Recent Viewed
Related Products
|
Product highlights
• Increases Testosterone by 60%
• Reduces DHT by 20%
• Decreases Estradiol by 9%
• Clinically proven safe and effective
The key compound in MYODROL™ has been demonstrated in clinical research to increase testosterone while decreasing DHT and Estradiol. Rest assured, MYODROL™ has been scientifically proven be safe and effective.
DON'T GET LEFT BEHIND
As pro-hormone products fade into supplement history, few options will remain for those seeking truly viable testosterone boosters. Inevitably, consumers will be left with a limited selection of mediocre or completely ineffective products.
Fortunately, Axis Labs is a forward-thinking company. Our researchers are continually peering into the future of the performance supplement industry. Long ago, we predicted the need for effective successors to pro-hormones. Therefore, Axis Labs has been engaged in an exhaustive quest for groundbreaking science in the arena of testosterone research.
A TIMELY BREAKTHROUGH
Axis Labs has earned a strong reputation for developing nothing short of the most effective testosterone-boosting products on the market. However, we are never satisfied. To us, our “best” is never good enough. We perpetually strive to achieve the absolute upper limits of testosterone production. That’s whey we were astounded with the implications of the clinical research behind our next groundbreaking product.
UNPRECEDENTED SYNERGY
Introducing MYODROL™ – The Advanced Testosterone Modulator. The key ingredient in MYODROL™ has been proven in clinical research to increase testosterone by 60%. Incredible, to be sure. However, there’s more to this story...much more.
The synergy of of compounds in MYODROL™ simultaneously decrease DHT and Estradiol. These “spin off” hormones typically increase in response to elevated testosterone. However, they elicit unwanted effects in the body. Two notorious examples are male pattern baldness, and increased fatty deposits around the abdominals and pecs. Simply put; by controlling DHT and Estradiol, MYODROL allows for the maximum possible benefits associated with elevated levels of testosterone.
TESTOSTERONE BOOSTER
MYODROL™ increases Testosterone by 60%
Testosterone is the king of anabolic hormones. Without adequate levels of it, men are at greater risk of experiencing decreased lean mass, reduced bone mineral density, depression and lack of energy.
When testosterone is at optimal levels, men experience greater strength, vitality, libido, mood and overall health.
Which of these scenarios works best for you?
MYODROL™ was shown in a published human clinical study to increase testosterone levels in healthy men by 60%.
5-Alpha REDUCTASE INHIBITION
MYODROL™ decreases DHT by 20%
Dihydrotestosterone (DHT) is a “spin off” hormone associated with increased levels of testosterone. Typically, an enzyme called 5-Alpha reductase “converts” excess testosterone into this compound. However, DHT is implicated in causing male pattern baldness. Even worse, DHT is cited as a contributing factor to poor prostate health.
A powerful component of MYODROL™ inhibits the enzymatic conversion of testosterone into DHT. Bottom line; less DHT conversion for greater levels of active testosterone in the body.
However, the battle for maximum testosterone availability doesn’t end with DHT.
AROMATASE INHIBITOR
MYODROL™ decreases Estadiol by 9%
Testosterone must run the gauntlet through an onslaught of aromatase enzymes. These enzymes work to convert testosterone into another “spin off” hormone called estradiol.
Elevated levels of estradiol promote the much-dreaded side-effects, gynecomastia (fatty deposits around the pecs) and excess accumulation of abdominal fat.
MYODROL™ effectively counters estradiol by inhibiting the aromatase enzyme.
The end result; a greater yield of anabolic testosterone in the body with decreased conversion to estradiol.
Directions
As a dietary supplement, take one capsules 3 times daily. Use continuously for 8 weeks followed by a period of 4 weeks of non-use. Stack MYODROL™ with Axis Labs HyperTEST for even greater results.
Store in a cool place. Protect from heat, light and moisture.
References
Fru Angwafor III, Mark L Anderson: An open label, dose response study to determine the effect of a dietary supplement on dihydrotestosterone, testosterone and estradiol levels in healthy males. J Int Soc Sports Nutr. 2008 Aug 12;5:12.
Morimoto I, Edmiston A, Horton R: Alteration in the metabolism of dihydrotestosterone in elderly men with prostate hyperplasia. J Clin Invest 1980, 66(3):612-615.
Vermeulen A: Clinical review 24: androgens in the aging male. J Clin Eendocrinol Metab 1991, 73(2):221-224.
Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morely JE, Schulman C, Wang C, Weidner W, Wu FC: Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl 2006, 27(2):135-137.
Hong BS, Ahn TY: Recent trends in the treatment of testosterone deficiency syndrome. Int J Urology 2007, 14:981-985.
Wang C, Swerdloff R: Editorial: Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab 2002, 87(4):1462-1466.
Chen J, Kim J, Dalton JT: Discovery and therapeutic promise of selective androgen receptor modulators. Mol Interv 2005, 5(3):173-188.
Walrand S, Boirie Y: Optimizing protein intake in aging. Current opinion. Clin Nut Met Care 2005, 8:89-94.
Movérare-Skrtic S, Venken K, Andersson N, Lindberg MK, Svensson J, Swanson C, Vanderschueren D, Oscarsson J, Gustafsson JA, Ohlsson C: Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity Research 2006, 14(4):662-672.
Montie JE, Pienta KJ: Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 1994, 43(6):892-895.
Strauch G, Perles P, Vergult G, Gabriel M, Gibelin B, Cummings S, Malbecq W, Malice MP: Comparison of finasteride (Proscar) and serenoa repens Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994, 26:247-252.
Staiman VR, Lowe FC: Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology 1997, 50(6):929-933.
Anderson ML: A preliminary investigation of the enzymatic inhibition of 5?-reductase and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and saw palmetto lipid extract in vitro. J Herbal Pharm 2005, 5(1):17-26.
Anderson ML: Method of inhibiting aromatase with specific dietary supplements. U.S. Patent application # 20040156926, 2004 Triarco Industries, Inc;
Morley JE, Kaiser F, Raum WJ, Perry RH, Flood JF, Jensen J, Silver AJ, Roberts E: Potentially predictive and manipulatable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 1997, 94:7537-7542.
|